Project Grant R00HL165091
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This $250,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Colorado State University to investigate the role of maternal gut microbiome and inflammation in preeclampsia and subsequent cardiometabolic disease in offspring. The key research aims are to: 1) Determine if the maternal gut microbiome contributes to pro- or anti-inflammatory short-chain fatty acid signaling at the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,831,848 to the University of Rochester to investigate how neonatal microbiome colonization impacts lung immunity and regeneration. The research aims to elucidate how early-life microbial dysbiosis remodels the developmental program in lung-resident lymphocytes and epithelial cells, contributing to chronic respiratory disease. Key...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $639,151 to Augusta University Research Institute, Inc. to investigate sex differences in the gut microbiome, immune system, and their role in salt-sensitive hypertension and kidney disease. The research will be conducted using Dahl salt-sensitive rat models and human samples from an opposite-sex twin cohort. The key...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $616,521 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Baylor College of Medicine to study the role of bacterial extracellular vesicles (EVs) in the gut-brain-hypertension axis. The project aims to: 1) identify the specific bacteria producing EVs that contribute to hypertension, 2) examine the effects of bacterial EVs on gut epithelial inflammation, and 3) define the impact of bacterial EVs on neuroinflammation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $249,000 to Brigham & Women's Hospital Inc. to develop methodologies to reveal the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The project aims to create a strain-resolved computational pipeline for reduced metagenomic sequencing to profile the blood microbiome, and a deep-learning framework to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
The federal Project Grant award R01HL179780 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $743,302 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on how gut microbe-derived lipids, specifically N-acyl amides, can signal through the host G protein-coupled receptor GPR119 to suppress chronic inflammation in cardiometabolic diseases like obesity, diabetes, and atherosclerosis....
This Project Grant award of $602,358, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to assess the contribution of epigenetics to cardiovascular risk in African American women. The project will identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can contribute to risk prediction assessments. The research will be conducted by the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...